Claire Hemmaway
Overview
Explore the profile of Claire Hemmaway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Russell N, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten L, et al.
J Clin Oncol
. 2024 Jan;
42(10):1158-1168.
PMID: 38215358
Purpose: To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients And Methods: One thousand thirty-three patients were randomly assigned...
2.
Kim A, OCallaghan A, Hemmaway C, Johney L, Ho J
Intern Med J
. 2023 Sep;
54(4):588-595.
PMID: 37718574
Background: Little is known about the end-of-life (EOL) experience and specialist palliative care use patterns of patients with haematological malignancies (HMs) in New Zealand. Aims: This retrospective analysis sought to...
3.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman S, Batten L, et al.
Blood Adv
. 2023 May;
7(16):4539-4549.
PMID: 37171402
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS) compared with 7+3 chemotherapy in older patients with secondary acute myeloid leukemia (AML); to date, there have been no randomized studies...
4.
Wong S, Offner M, Hu R, Hemmaway C
N Z Med J
. 2023 Mar;
136(1572):10-18.
PMID: 36958317
Aim: Acute lymphoblastic leukaemia/lymphoma (ALL) is a rare disease that requires an intensive chemotherapy regimen for successful treatment. This is a single-centre retrospective audit to assess the treatment outcomes in...
5.
Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, et al.
BMC Cancer
. 2022 Nov;
22(1):1174.
PMID: 36376888
Background: For patients with acute myeloid leukaemia (AML), the only potentially curative treatment is intensive chemotherapy (IC). This is highly toxic, particularly for patients > 60 years, potentially leading to...
6.
Pettit T, Proffit E, Reid J, Dobinson H, Waugh V, Sue L, et al.
J Adolesc Young Adult Oncol
. 2022 Aug;
12(3):366-375.
PMID: 35917507
To identify the spectrum and nature of survivorship barriers experienced by New Zealand's adolescent and young adult (AYA) cancer survivor population. In addition, we explore associations between survivorship barriers and...
7.
Ferreri A, Cwynarski K, Pulczynski E, Fox C, Schorb E, Celico C, et al.
Leukemia
. 2022 May;
36(7):1870-1878.
PMID: 35562406
219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B),...
8.
Angoro B, Motshakeri M, Hemmaway C, Svirskis D, Sharma M
Clin Chim Acta
. 2022 Apr;
531:157-167.
PMID: 35398023
Non-transferrin-bound iron (NTBI) is an important biomarker related to the iron loading status of patients with certain diseases. NTBI is a highly toxic form of iron capable of generating free...
9.
Dennis M, Thomas I, Ariti C, Upton L, Burnett A, Gilkes A, et al.
Blood Adv
. 2021 Oct;
5(24):5621-5625.
PMID: 34597366
Survival for older patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy is unsatisfactory. Standard nonintensive therapies have low response rates and only extend life by a few months....
10.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen M, et al.
Br J Haematol
. 2021 May;
194(2):298-308.
PMID: 33961292
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. Because they are perceived to be unfit for, unwilling to receive, or unlikely to...